Get started
Author

Samir Turk

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
2019 · Kausik K Ray, Helen M Colhoun, et al. · The Lancet Diabetes & Endocrinology · 315
PDF
The Changing Landscape for Stroke Prevention in AF
2017 · Menno V. Huisman, Kenneth J. Rothman, et al. · Journal of the American College of Cardiology · 280
PDF
Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
2016 · Sean D. Pokorney, Jonathan P. Piccini, et al. · Journal of the American Heart Association · 201
PDF
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
2021 · Gregory G. Schwartz, Gregory G. Schwartz, et al. · Journal of the American College of Cardiology · 148
PDF
Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials
2003 · M. Vrecer, S. Turk, et al. · International Journal of Clinical Pharmacology and Therapeutics · 142
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
2022 · Emil Hagström, P. Gabriel Steg, et al. · Circulation · 118
PDF
Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry
2023 · Giulio Francesco Romiti, Bernadette Corica, et al. · EClinicalMedicine · 45
PDF
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
2021 · Gregory G. Schwartz, Michael Szarek, et al. · Diabetes Care · 40
PDF
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
2022 · Gregory Y. H. Lip, Agnieszka Kotalczyk, et al. · Clinical Research in Cardiology · 33
PDF
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
2025 · P. Gabriel Steg, Michael Szarek, et al. · Circulation · 26
PDF
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
2024 · Shaun G Goodman, Philippe Gabriel Steg, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 25
PDF
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation
2020 · Benjamin A. Steinberg, DaJuanicia N. Holmes, et al. · Circulation Arrhythmia and Electrophysiology · 12
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry
2023 · Wern Yew Ding, Ameenathul Mazaya Fawzy, et al. · Journal of Thrombosis and Thrombolysis · 7
Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry
2020 · George Ntaios, Menno V. Huisman, et al. · Hellenic Journal of Cardiology · 3
PDF
Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
2022 · Gregory Y. H. Lip, Agnieszka Kotalczyk, et al. · Clinical Research in Cardiology
PDF
Works count: 15
Citation count: 1,394
H-index: 12
I10-index: 12
Year
Topic
Type